88 results about "Cardiac chest pain" patented technology

A method is disclosed for electrically stimulating a cranial nerve, especially a vagus nerve, to treat or alleviate angina pectoris. Pain is lessened or prevented by application of predetermined therapeutic electrical signal to a selected location on the cranial nerve of a patient using an implanted neurostimulating device. Such method employs selective application of electrical signals to a predetermined location on the nerve to alter the activity of the nerve and cause dilation of a coronary artery in the patient, which in turn provides complete or partial relief of chest pain or deters the onset of such pain.

The subject invention relates to the detection, diagnosis and risk stratification of clinical events such as acute coronary syndrome, in patients with signs and symptoms of suspected cardiac origin. In one embodiment, a clinical event in a patient is diagnosed by obtaining the patient's ECG, and at least one in vitro diagnostic assay, preferably an assay for a marker of ischemia, and optionally in vitro diagnostic assays for necrotic markers or other cardiac indicators, and combining the foregoing results in an algorithm to provide a diagnosis or a risk stratification of the clinical condition.

The present invention relates to a method for diagnosing myocardial infarction in a subject presenting with chest pain. The method is based on the determination of an amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. Moreover, the present invention envisages a method for ruling in myocardial infarction and a method for ruling out myocardial infarction. The said methods are also based on the determination of the amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample.

The invention relates to a quality control method of Yixinshu traditional chinese medicine preparation for nourishing qi, restoring pulse, and activating blood circulation to dissipate blood stasis, belonging to medicine domain. The Yixinshu traditional chinese medicine preparation is composed of panax, astragalus root, radix salviae miltiorrhizae, lityturf root, chinese magnoliaving, chuanxiong rhizome and haw, with ability of nourishing qi, restoring pulse, activating blood circulation to dissipate blood stasis, nourishing yin and production of body fluid, applicable for the patients who suffer for deficiency of both vital energu and yin, heart-throb knotted pulse, chest oppression, chest pain, and angina pectoris of coronary heart disease. At present, on clinical usage, it is applied extensively in the treatment of angina pectoris, myocardial ischemia, various type of arrhythmias, atrial premature beat, chest pain, angina pectoris of coronary heart disease and so on. The said quality control method provides the criterion of detection, means of detection, technical method and so on for the associated production and detection mechanism, therefore the quality of Yixinshu traditional chinese medicine preparation can be better controlled to ensure the safety of the said preparation. The quality method can better guide the production to make the production process control more strict and reasonable, therefore the users could have an overall acquaintance with the product quality.

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition provides a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight heparin. Preferably the low molecular weight heparin is administered up to revascularisation. The methods are also useful for treatment of unstable angina and not worsening chest pain and for treatment of non-Q-wave myocardial infarction (mild heart attack).

The invention discloses a cardiovascular disease risk prediction network model based on multiple parameters and a construction method thereof, relates to a risk prediction model, and solves the problems that an existing cardiovascular disease risk prediction model cannot predict multiple physiological parameters and is not ideal in prediction effect. The method comprises the following steps: establishing a cardiovascular disease data set; preprocessing the data set data, and dividing the data set into a training set and a test set according to the ratio of the number of the training set data to the number of the test set data being 7: 3; performing model construction: both the training set and the test set comprise samples and labels, model training is conducted on training set data through the minimum error of forward propagation and reverse propagation in the training process, and the trained model is evaluated through the test set data. The risk of suffering from cardiovascular diseases is evaluated by detecting multiple physiological parameters such as age, gender, chest pain type, resting blood pressure, serum cholesterol, fasting blood glucose, resting electrocardiogram, maximum heart rate and the like of a person.

The invention provides a traditional Chinese medicine composition for curing tuberculous exadative pleurisy. The bulk drugs of the traditional Chinese medicine composition include flos farfarae, root bark of white mulberry, Chinese yam, euphorbia kansui, rhizoma panacis majoris, folium eriobotryae, radix stemonae, Chinese-date, inula flower, Chinese mahonia stems, rhizoma zingiberis, rhizoma sparganii, flowers carthami, folia perillae acutae, allium macrostemon, selaginella tamariscina, vine of multiflower knotweed, exocarpium, changium smyrnioides, poria cocos, semen coicis, turmeric, schisandra chinensis, semen lepidii, radix polygonati officinalis, rhizoma anemarrhenae, dayflower, polygonum cuspidatum, adenophora tetraphylla and kaladana. The traditional Chinese medicine composition reduces untoward effect of hydrothorax absorption, shortens course of disease, reduces pleural adhesions, pleural thickening and chest pain, enables hydrothorax absorption of patients to be quick, remarkably alleviates chest pain, and greatly reduces rate of pachynsis pleurae or pleural adhesion, thereby overcoming side effects caused by western drug therapy and having a certain curative effect on curing tuberculous exadative pleurisy.

The invention belongs to the technical field of medicines and relates to a traditional Chinese medicine composition used for treating coronary heart disease angina and a preparation method thereof. The traditional Chinese medicine composition used for treating coronary heart disease angina provided by the invention is prepared from the following traditional Chinese medicine composition raw drugs in parts by weight: 220-260 parts of vinegar-processed corydalis tuber, 4-12 parts of musk, 4-12 parts of storax, 100-140 parts of Szechuan lovage rhizome, 100-140 parts of ginseng and 6-18 parts of borneol. The traditional Chinese medicine composition provided by the invention has the efficacies of promoting the circulation of qi and resuscitating, activating blood and dissolving stasis as well as activating meridians to stop pain and is used for treating chest pain, choking sensation in chest, swelling pain at ribs, shortness of breath and palpitation which are caused by Qi-stagnation and blood stasis type coronary heart disease angina.

The invention discloses an analgesic bone rheumatoid plaster. The analgesic bone rheumatoid plaster has the functions of relaxing tendons, activating blood circulation, removing blood stasis, dispelling pathogenic wind, dispelling cold, removing dampness, stimulating the menstrual flow, activating collaterals, invigorating bone, relieving pain, resolving hard mass, and the like. The indications comprise bumps, fall injuries, pain on wounds, intercostal neuralgia, lumbar sprain, chest pain, pain in neck, shoulder, waist and lower extremities, rheumatism, rheumatoid arthritis, bone hyperplasia, bone spur, gout, bone fractures, neuropathic pain, and the like, and the efficacy is remarkable. The analgesic bone rheumatoid plaster is characterized in that the plaster can be directly pasted without heating when in application, and the paste oil can not be flowed anywhere and only leave a light mark, thereby not affecting the sanitation and not generating a wound surface on the skin by long-term application.

The invention discloses a medicine composition for treating cardio-cerebral-vascular diseases and a preparation method and application thereof, belonging to the field of traditional Chinese medicines. The effective component of the medicine composition comprises total sapogenin and total alkaloid extracted from traditional Chinese herb trichosanthes kirilowii Maxim and allium macrostemon. The medicine composition which can be made into proper preparation forms has good treatment effects on coronary disease, angina, arteriosclerosis, chest pain, hyperlipoidemia and the like. The invention also discloses preparation methods of the total sapogenin and the total alkaloid.

The present invention provides methods and markers for characterizing a subject's, particularly a human subject risk of having cardiovascular disease. The present invention also provides methods of characterizing a subject's risk of developing cardiovascular disease. In another embodiment, the present invention provides methods for characterizing a subject's risk of experiencing a complication of cardiovascular disease or major adverse cardiac event within 1, 3, or 10 years. In another embodiment, the present invention provides a method for determining whether a subject presenting with chest pain is at risk near term of experiencing a heart attack or other major adverse cardiac event. The present methods are especially useful for identifying those subjects who are in need of highly aggressive CVD therapies as well as those subjects who require no therapies targeted at inhibiting or preventing CVD or complications of CVD.

The invention discloses a deer heart blood soft capsule, which is characterized by consisting of the following bulk pharmaceuticals in parts by weight: 40g of deer heart blood, 30g of lucid ganoderma, 5g of rhodiola rosea, 3g of snow lotus, 10g of red ginseng, 5g of straight ladybell root, 10g of royal jelly, 10g of astragalus, 5g of American ginseng and 5g of blueberry. The deer heart blood of deer, and lucid ganoderma, rhodiola rosea and snow lotus which are extracted at a high concentration are prepared into a soft capsule, so that the medicinal activity is ensured fully, the medicament efficiency is increased, and the defect of poor absorptivity of the conventional roughly-processed product is overcome. The deer heart blood soft capsule has remarkable effects on coronary heart disease myocardial infarction, arrhythmia, myocardial ischemia, congestive heart failure, myocarditis, a rheumatic heart disease, cerebral thrombosis, angina, mental confusion, short breath, dizziness, palpitation, chest distress, chest pain, hypertension, hyperlipidemia and the like.

The invention relates to a medicated wine preparation for curing the obstruction of qi in the chest and chest pain caused by cold phlegm, stagnation of the vital energy, blood stasis and retinervus blocking, which is composed of the drugs of Mongolian snakegourd, bulb of long stamen onion, cassia twig, asarum, Chinese angelica root-tip, rhizome of Sichuan lovage, red sage root, curcuma root, cyperirhizome, corydalis tuber, powder of notoginseng, licorice, cereal wine and so on. The invention is used for preventing and curing the obstruction of qi in the chest and chest pain caused by cold phlegm, stagnation of the vital energy, blood stasis and retinervus blocking. The medicated wine preparation has the advantages that the raw materials are extensive, the preparation is simple, the oral administration is convenient, the targeting force is strong, the guiding force is strong, the curative effect is good, toxic and side effects do not exist, and the total effective rate of the clinical expectant treatment is 100 percent, and the gap that the medicated wine has the functions of warming heart-yang, regulating vital energy, facilitating qi, resolving phlegm, promoting blood circulation to dispel blood stasis, relieving the cold and alleviating pain, and the field blank of curing the obstruction of qi in the chest and chest pain is filled up. The invention is an innovation of the clinical medical care medicated wine culture for the diseases such as obstruction of qi in the chest and chest pain of human beings at present.

The invention belongs to the medical technical field and discloses a drug combination for the cardiovascular disease and the preparation method of the drug combination. The drug combination contains the pharmacodynamic components of the raw materials of drugs of danshen root, Szechwan lovage rhizome, panax notoginseng, milkvetch root and storax. In order to achieve a better curative effect, a leech, tonka beans and peach nuts can also be added into the drug combination; in order to further improve the curative effect, rosewood, axillary choerospondias fruit and earthworms can be added into the drug combination. The drug combination of the invention has the efficacies of promoting the circulation of qi to induce resuscitation, activating blood circulation for removing blood stasis, dredging channels for alleviating pain etc. and is used for preparing the drugs for remedying the cerebral infarction convalescence of the coronary heart disease, the angina pectoris or the arteriosclerosis, the syndrome of which belong to the qi stagnation and blood stasis with the symptoms of chest pain, oppression in the chest, shortness of breath, heart throb, inefficaciousness of limbs, inarticulacy etc. The drug combination of the invention can be made into any preparation type, which is acceptable in the clinic and the pharmacy, and the oral preparation is preferential.

The invention provides a medicine for treating coronary heart disease and the symptoms of chest stuffiness, chest pain and heart palpitation, which comprises notoginseng, root of red rooted saliva, ganoderma lucidum, kudzu vine root, Ligusticum wallichii, dalbergia wood, bark of eucommia.

The current invention presents a dietary supplement obtained from a mixture of melatonin, vitamins and aminoacids for healing or regressing symptoms of gastroesophageal reflux disease (such as heartburn, regurgitation, dysphagia, coughing, hoarseness, chest pain and odynophagia), gastritis and several types of ulcerations.

A traditional Chinese medicine preparation for treating coronavirus pneumonia cough is prepared according to a basic traditional Chinese medicine formula comprising the following traditional Chinese medicine raw materials in parts by weight: 6 to 15 parts of trichosanthes peel, 6 to 15 parts of rhizoma pinelliae preparata, 3 to 9 parts of scutellaria baicalensis, 3 to 9 parts of roasted radix stemonae, 5 to 15 parts of radix peucedani, 5 to 15 parts of rhizoma cynanchi stauntonii, 3 to 9 parts of roasted liquorice, 6 to 12 parts of radix platycodonis, 5-15 parts of herba schizonepetae, 5-15 parts of radix asteris and 5-15 parts of pericarpium citri reticulatae. The traditional Chinese medicine preparation is simple and appropriate in compatibility, and is fully verified in curative effectthrough clinical application. The traditional Chinese medicine preparation can effectively relieve COVID-19 cough and expectoration symptoms, the lung function can be recovered to a certain extent, and the breathing quality of a patient is improved; and respiratory system inflammatory response comprehensive symptoms such as chest distress, fatigue, acute breath, asthma and chest pain of COVID-19 patients are improved.

The invention relates to a traditional Chinese medicine composition for treating qi-stagnancy and blood stasis type coronary heart disease. The traditional Chinese medicine composition is prepared from the following raw medicinal materials: radix bupleuri, fructus aurantii, white paeony root, rhizoma cyperi, corydalis tuber, ligusticum wallichii, lumbricus and liquorice. The invention further provides application of the traditional Chinese medicine composition. The traditional Chinese medicine composition disclosed by the invention has the advantages that the traditional Chinese medicine composition disclosed by the invention achieves the effects of effectively improving the clinical curative effects of the qi-stagnancy and blood stasis type coronary heart disease, improving abnormal feeling of a patient, dispersing the liver and rectifying qi and promoting blood circulation to remove meridian obstruction, patients suffering from severe chest distress and chest pain can be alleviated to be patients suffering from slight chest distress and chest pain, even the symptoms such as the chest distress and chest pain of the patients are eliminated, stenocardia symptoms of the patients can be improved, and severe stenocardia is alleviated to be moderate stenocardia and even alleviated to be slight stenocardia.

The present invention provides a molecular network, devices, and assays for early diagnosis of angina patients experiencing acute chest pain with negative Troponin, and it reflects on disease progression and severity. The invention also allows for the diagnosis of angina in suspected patients with history of chest pain; differentiates between angina patients and acute myocardial infarction; as well as diagnose coronary artery disease patients from other non-cardiac and healthy individuals. The present invention indicates that the downregulation of Nourin IncCTB9H12.4 in coronary artery disease patients compared to non-cardiac and healthy controls, is significantly associated with upregulation of miR_106b and miR_137 resulting in overexpression of mRNA ANAPC11 and mRNA FTLH-17; respectively. Therefore, the invention provides a novel non-invasive good positive test to diagnose angina patients which also, has a good negative test to exclude chest pain non-angina patients and healthy individuals.

The invention discloses a chest pain patient time management system and a chest pain patient time management method. The chest pain patient time management system comprises: a server, an intelligent terminal, and a plurality of Internet of Things equipment which are distributed in a plurality of specific places and capable of identifying intelligent terminals in the corresponding specific places,recording the timestamp of the intelligent terminals entering and leaving the specific places and uploading the timestamp to the server for statistical analysis. The server transmits and feeds back the prompt command to the intelligent terminals through the Internet of Things equipment to make corresponding prompts, and generates patient flow records and patient data reports on the server side. According to the invention, the time records of important nodes of chest pain patients are automatically recorded by matching the Internet of things information acquisition equipment with the intelligent terminals, so that the functions of concise, convenient and automatic time record acquisition, storage, early warning, reminding and the like are realized, the workload of medical workers is reducedon the basis of providing the integrity of time record data, the real-time data is utilized for intelligent analysis and quality control management, and the standardization of time management is further promoted.

The invention discloses a stasis-expelling blood-activating pain-relieving soup prepared by boiling the following raw materials in parts by weight and water: 30-40 parts of radix rehmanniae, 10-14 parts of fried peach kernels, 10-14 parts of red flower, 10-14 parts of angelica sinensis, 7-13 parts of ligusticum wallichii, 10-20 parts of root of common peony, 10-15 parts of radix bupleuri, 7-13 parts of liquorice, 12-15 parts of the root of bidentate achyranthes, 5-8 parts of pericarpium citri reticulatae, 7-13 parts of pericarpium citri reticulatae viride, 7-13 parts of grass hovenia dulcis, 12-18 parts of processed rhizoma cyperi and 10-14 parts of platycodon grandiflorum. By utilizing the stasis-expelling blood-activating pain-relieving soup, coronary heart disease, angina, myocardial infarction, heart disease, insufficient blood supply and myocardial ischemia caused by blood stasis qi stagnation and body ache caused by Bruce bacillus can be effectively treated, and the effects on diseases of chest distress, chest pain, palpitation, cardiopalmus, sweating, shortness of breath, gas compression, palpitation, fear, cowardice, troubled sleep, intermittent pulse, severe palpitation, and the like are obvious.

The invention relates to a medicinal oral preparation of musk drop pill with the functions of arousing coma, relieving pain and treating precordial pain, chest pain, the drop pill has the advantages of high biological availability, quick-speed medicine release, quick-speed effect, less toxic and side effects, higher medicinal content, smaller amount of administration, accurate administration dosage, easy administering, low price, and facilitated carrying. The medicine is prepared through the conventional drop pill preparing process.

A Chinese medicine 'Yindanxintai' in the form of particle, capsule, micropill, or tablet for treating qi obstruction of chest and chest pain is prepared from gingko leaf, red sage root, gynostemma pentaphyllum and borneol. Its preparing process is also disclosed.

A preparation method for a traditional Chinese medicine for treating depressed anger liver-damaging type chest pain syndrome belongs to the technical field of preparation methods for traditional Chinese medicines. At present, isosorbide mononitrate is generally used for treating the depressed anger liver-damaging type chest pain syndrome, but commonly causes adverse effects of giddiness, dizzy giddy, faint and flushing of faces and necks of patients due to postural hypotension. The technical scheme includes that fiveleaf akebia fruits, truestar anisetree, murraya paniculata, aspongopus, elecampane, toosendan fruits, caesalpinia sepiaria, costustoot, ambergris, red costustoot, fingered citron, Chinese asafoetida, rose, green tangerine peels, radix aristolochiae, radix curcumae, artemisia rupestris, achyranthes aspera, ligusticum chuanxiong hort, Chinese rose, salvia miltiorrhiza, impatiens balsamina, fructus polygoni orientalis, herba euphorbiae humifusae, rhizoma corydalis, safflower carthamus, dai-dai flower, pomelo and liquorice are taken and soaked in water, then decocted by small fire and filtered, and after residues are removed, decocted liquid medicine is the traditional Chinese medicine for treating the depressed anger liver-damaging type chest pain syndrome. The preparation method has the advantages of simple preparation, low toxic and side effects of the prepared liquid medicine, short treatment course and high recovery rate. The traditional Chinese medicine contains proper quantities of monarch, minister, assistant and guide medicines.

The invention specifically relates to a levocarnitine sesquihydrate, which belongs to the technical field of medicines. The levocarnitine sesquihydrate obtained in the invention contains one and a half crystal water and has the advantages of a high purity and good stability, having non-obvious moisture absorption and weight gain even under the condition of high humidity. The invention also relates to application of the levocarnitine sesquihydrate in preventing and mitigating myocardial damage, in mitigating and alleviating symptoms of chest pain, in treating coronary heart disease, angina pectoris, heart failure, myocardial infarction and cerebral infarction, in auxiliary treatment of renal disease, chronic pulmonary heart disease, male sterility, acquired immune deficiency syndrome, intermittent claudication, as well as acute and chronic hepatitis, cirrhosis, chronic hepatic insufficiency, muscular atrophy, diabetes and bad postpartum uterus contraction, etc.

The invention discloses a health drink capable of preventing and treating sub-health and atherosclerosis; the health drink is prepared from the following raw materials in parts by weight: 3-8 parts of American ginseng, 5-15 parts of longan aril, 6-12 parts of fruit of Chinese wolfberry, 2-8 parts of dendrobe, 10-20 parts of rhizoma polygonati, 2-6 parts of bidens pilosa, 3-8 parts of ampelopsis grossedentata, 3-8 parts of glossy privet fruit and 3-10 parts of eclipta alba. The health drink disclosed by the invention has functions of benefiting qi and nourishing yin, nourishing heart and tonifying spleen, and nourishing liver and kidney, and meanwhile, the health drink has effects of promoting immunity, resisting oxidation, resisting inflammation, resisting aging, resisting tumors, resisting stress, reducing blood sugar, reducing blood pressure, reducing blood fat and the like. The health drink disclosed by the invention is significant in effect on treating sub-health status and atherosclerosis, mainly represented in symptom of fatigue, or accompanied with symptoms of dizziness, feverish dysphoria, amnesia, constipation, dry throat, hidrosis, insomnia, chest distress, chest pain, shortness of breath and the like.